NPHLA Daily
NPHLA Daily
Monday, October 5, 2026 · 3-minute read
Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.
Top development today
What changed today in Metabolic: 1 new study
NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in Molecular metabolism: “Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of concept”.
Metabolic signal
Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of concept
From Molecular metabolism.
One thing worth watching
Comments close: Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and…
October 29, 2026 — verified from the Federal Register comments_close_on.
5 things to know
Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.